Graft Polymer (UK) PLC (LSE:GPL) has begun a fresh chapter in its corporate story with a new name: Solvonis Therapeutics PLC.
In a statement, the company said the change better reflects its growing focus on developing innovative treatments for mental health and substance use disorders. A new website, www.solvonis.com, will soon go live to align with the updated identity.
CEO Anthony Tennyson explained: "The name Solvonis Therapeutics is derived from the Latin root solv, meaning 'to release, unbind, and free.'
"This change symbolises our commitment to freeing individuals from the constraints of mental health and substance use disorders through innovative therapeutic solutions."
"Solvonis Therapeutics' new name and direction align with our core mission to improve the lives of those suffering from mental health and addiction conditions, particularly focusing on developing novel treatments that empower patients to regain control of their lives."
The switch will officially take effect on Wednesday (Jan 15), and it will include a new ticker symbol, SVNS.